Body-fat abnormalities in patients with HIV: Progress and challenges

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The introduction of newer antiretroviral drugs has provided greater levels of HIV suppression with fewer of the metabolic effects, lipoatrophy, and body habitus changes associated with earlier therapies. Previously classified under the collective term, lipodystrophy, lipoatrophy and body-fat changes are now known to occur independently in some HIV-infected patients, depending on the type and duration of antiretroviral therapy and a myriad of factors including HIV infection alone that contribute significantly to these changes. This article reviews the current scientific literature and recent clinical trial results that distinguish lipoatrophy or dyslipidemia pathophysiologically from body-fat changes seen as central and peripheral lipohypertrophy and fat redistribution, as well as the nature and extent of changes associated with HIV infection alone and newer antiretroviral therapies. This information may assist physicians in identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize these changes without loss of virologic suppression.

Original languageEnglish (US)
Pages (from-to)292-305
Number of pages14
JournalJournal of the International Association of Physicians in AIDS Care
Volume7
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Adipose Tissue
HIV
HIV Infections
Literature
Lipodystrophy
Dyslipidemias
Secondary Prevention
Therapeutics
Fats
Clinical Trials
Physicians
Pharmaceutical Preparations

Keywords

  • antiretroviral therapy
  • body fat
  • HIV infection
  • lipoatrophy

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology
  • Dermatology
  • Medicine(all)

Cite this

@article{f95f023be646416ebe27f91c6c314230,
title = "Body-fat abnormalities in patients with HIV: Progress and challenges",
abstract = "The introduction of newer antiretroviral drugs has provided greater levels of HIV suppression with fewer of the metabolic effects, lipoatrophy, and body habitus changes associated with earlier therapies. Previously classified under the collective term, lipodystrophy, lipoatrophy and body-fat changes are now known to occur independently in some HIV-infected patients, depending on the type and duration of antiretroviral therapy and a myriad of factors including HIV infection alone that contribute significantly to these changes. This article reviews the current scientific literature and recent clinical trial results that distinguish lipoatrophy or dyslipidemia pathophysiologically from body-fat changes seen as central and peripheral lipohypertrophy and fat redistribution, as well as the nature and extent of changes associated with HIV infection alone and newer antiretroviral therapies. This information may assist physicians in identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize these changes without loss of virologic suppression.",
keywords = "antiretroviral therapy, body fat, HIV infection, lipoatrophy",
author = "Bedimo, {Roger J.}",
year = "2008",
month = "12",
doi = "10.1177/1545109708328931",
language = "English (US)",
volume = "7",
pages = "292--305",
journal = "Journal of the International Association of Physicians in AIDS Care",
issn = "1545-1097",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Body-fat abnormalities in patients with HIV

T2 - Progress and challenges

AU - Bedimo, Roger J.

PY - 2008/12

Y1 - 2008/12

N2 - The introduction of newer antiretroviral drugs has provided greater levels of HIV suppression with fewer of the metabolic effects, lipoatrophy, and body habitus changes associated with earlier therapies. Previously classified under the collective term, lipodystrophy, lipoatrophy and body-fat changes are now known to occur independently in some HIV-infected patients, depending on the type and duration of antiretroviral therapy and a myriad of factors including HIV infection alone that contribute significantly to these changes. This article reviews the current scientific literature and recent clinical trial results that distinguish lipoatrophy or dyslipidemia pathophysiologically from body-fat changes seen as central and peripheral lipohypertrophy and fat redistribution, as well as the nature and extent of changes associated with HIV infection alone and newer antiretroviral therapies. This information may assist physicians in identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize these changes without loss of virologic suppression.

AB - The introduction of newer antiretroviral drugs has provided greater levels of HIV suppression with fewer of the metabolic effects, lipoatrophy, and body habitus changes associated with earlier therapies. Previously classified under the collective term, lipodystrophy, lipoatrophy and body-fat changes are now known to occur independently in some HIV-infected patients, depending on the type and duration of antiretroviral therapy and a myriad of factors including HIV infection alone that contribute significantly to these changes. This article reviews the current scientific literature and recent clinical trial results that distinguish lipoatrophy or dyslipidemia pathophysiologically from body-fat changes seen as central and peripheral lipohypertrophy and fat redistribution, as well as the nature and extent of changes associated with HIV infection alone and newer antiretroviral therapies. This information may assist physicians in identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize these changes without loss of virologic suppression.

KW - antiretroviral therapy

KW - body fat

KW - HIV infection

KW - lipoatrophy

UR - http://www.scopus.com/inward/record.url?scp=62249160796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62249160796&partnerID=8YFLogxK

U2 - 10.1177/1545109708328931

DO - 10.1177/1545109708328931

M3 - Article

C2 - 19056708

AN - SCOPUS:62249160796

VL - 7

SP - 292

EP - 305

JO - Journal of the International Association of Physicians in AIDS Care

JF - Journal of the International Association of Physicians in AIDS Care

SN - 1545-1097

IS - 6

ER -